nitrendipine has been researched along with Kidney Diseases in 11 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Calcium channel blocking agents have been shown experimentally and clinically to ameliorate ischaemic and toxic renal injury." | 2.66 | Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial. ( Junge, W; Küfner, A; Neumayer, HH; Wenning, A, 1989) |
| " The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine." | 2.37 | Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ( Eichelbaum, M; Fischer, C; Kuhlmann, U; Machleidt, C; Mast, V; Mikus, G, 1988) |
| "Gentamicin was administered intramuscularly in a dose of 40 mg/kg/day for 12 days to adult Fischer rats." | 1.27 | Nitrendipine protects against aminoglycoside nephrotoxicity in the rat. ( Lee, SM; Michael, UF; Pattison, ME, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishimitsu, T | 1 |
| Honda, T | 1 |
| Ohta, S | 1 |
| Akashiba, A | 1 |
| Takahashi, T | 1 |
| Kameda, T | 1 |
| Yoshii, M | 1 |
| Minami, J | 1 |
| Takahashi, M | 1 |
| Ono, H | 1 |
| Matsuoka, H | 1 |
| Liu, LL | 1 |
| Li, QX | 1 |
| Xia, L | 1 |
| Li, J | 1 |
| Shao, L | 1 |
| Remuzzi, A | 1 |
| Imberti, O | 1 |
| Puntorieri, S | 1 |
| Malanchini, B | 1 |
| Macconi, D | 1 |
| Magrini, L | 1 |
| Bertani, T | 1 |
| Remuzzi, G | 1 |
| Barenbrock, M | 1 |
| Colmorgen, U | 1 |
| Firschka, E | 1 |
| Gellert, J | 1 |
| Lippert, J | 1 |
| Schröder, K | 1 |
| Spieker, C | 1 |
| Voigt-Ladner, G | 1 |
| Wagner, K | 1 |
| Neumayer, HH | 2 |
| Lee, SM | 2 |
| Pattison, ME | 1 |
| Michael, UF | 2 |
| Eichelbaum, M | 1 |
| Mikus, G | 1 |
| Mast, V | 1 |
| Fischer, C | 1 |
| Kuhlmann, U | 1 |
| Machleidt, C | 1 |
| Junge, W | 1 |
| Küfner, A | 1 |
| Wenning, A | 1 |
| Kacew, S | 1 |
| Aronoff, GR | 1 |
| Sloan, RS | 1 |
| Edgar, B | 1 |
| Aurell, M | 1 |
| Johnsson, G | 1 |
| Regårdh, CG | 1 |
| Shansky, C | 1 |
1 review available for nitrendipine and Kidney Diseases
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease.
Topics: Humans; Kidney Diseases; Liver Diseases; Nitrendipine | 1988 |
2 trials available for nitrendipine and Kidney Diseases
| Article | Year |
|---|---|
A multicenter, randomized, double-blind, placebo-controlled, two-year trial to study the effect of nitrendipine on chronic renal transplant function.
Topics: Adolescent; Adult; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind Method; Drug Ther | 1995 |
Prevention of radiocontrast-media-induced nephrotoxicity by the calcium channel blocker nitrendipine: a prospective randomised clinical trial.
Topics: Contrast Media; Double-Blind Method; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; M | 1989 |
8 other studies available for nitrendipine and Kidney Diseases
| Article | Year |
|---|---|
Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Blood Pressure; C | 2006 |
Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats.
Topics: Amlodipine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Blood Urea Nitrogen; Calci | 2007 |
Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats.
Topics: Alpha-Globulins; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Electrop | 1994 |
Nitrendipine protects against aminoglycoside nephrotoxicity in the rat.
Topics: Acetylglucosaminidase; Aminoglycosides; Animals; Anti-Bacterial Agents; Gentamicins; Kidney Cortex; | 1987 |
Inability of nitrendipine to protect against gentamicin nephrotoxicity in the rat.
Topics: Animals; Gentamicins; Kidney Cortex; Kidney Diseases; Male; Nitrendipine; Phospholipids; Rats; Rats, | 1989 |
The protective effect of nitrendipine on gentamicin acute renal failure in rats.
Topics: Acute Kidney Injury; Animals; Female; Gentamicins; Hemodynamics; Kidney; Kidney Diseases; Kidney Fun | 1985 |
Nitrendipine kinetics in normal and impaired renal function.
Topics: Adult; Aged; Antihypertensive Agents; Biotransformation; Creatinine; Humans; Intestinal Absorption; | 1985 |
Effects of impaired renal function on the pharmacokinetics of felodipine.
Topics: Adult; Antihypertensive Agents; Felodipine; Humans; Kidney Diseases; Male; Middle Aged; Nitrendipine | 1987 |